Switch Study of Existing Atypical Antipsychotics to Bifeprunox
Public ClinicalTrials.gov record NCT00347425. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
Study identification
- NCT ID
- NCT00347425
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 286 participants
Conditions and interventions
Conditions
Interventions
- Aripiprazole Drug
- Olanzapine Drug
- Risperidone Drug
- Quetiapine Drug
- Ziprasidone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2006 (Type not available)
- Primary completion
- Feb 2008 (Actual)
- Completion
- Feb 2008 (Actual)
- Last update posted
- May 21, 2008
2006 – 2008
United States locations
- U.S. sites
- 63
- U.S. states
- 24
- U.S. cities
- 57
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 148 | Birmingham | Alabama | — | — |
| Site 194 | Little Rock | Arkansas | — | — |
| Site 178 | Anaheim | California | — | — |
| Site 167 | Cerritos | California | — | — |
| Site 189 | Cerritos | California | — | — |
| Site 183 | Culver City | California | — | — |
| Site 140 | Garden Grove | California | — | — |
| Site 162 | La Palma | California | — | — |
| Site 190 | Long Beach | California | — | — |
| Site 173 | Oceanside | California | — | — |
| Site 175 | Paramount | California | — | — |
| Site 136 | Pasadena | California | — | — |
| Site 184 | Sacramento | California | — | — |
| Site 152 | San Diego | California | — | — |
| Site 186 | San Diego | California | — | — |
| Site 133 | Santa Ana | California | — | — |
| Site 171 | Torrance | California | — | — |
| Site 197 | Boca Raton | Florida | — | — |
| Site 156 | Gainesville | Florida | — | — |
| Site 188 | Hialeah | Florida | — | — |
| Site 193 | Jacksonville | Florida | — | — |
| Site 154 | Miami | Florida | — | — |
| Site 163 | North Miami | Florida | — | — |
| Site 168 | North Miami | Florida | — | — |
| Site 166 | Orange City | Florida | — | — |
| Site 124 | Orlando | Florida | — | — |
| Site 187 | Tampa | Florida | — | — |
| Site 161 | Atlanta | Georgia | — | — |
| Site 128 | Augusta | Georgia | — | — |
| Site 122 | Decatur | Georgia | — | — |
| Site 174 | Chicago | Illinois | — | — |
| Site 164 | Indianapolis | Indiana | — | — |
| Site 172 | Lake Charles | Louisiana | — | — |
| Site 182 | Shreveport | Louisiana | — | — |
| Site 121 | Glen Burnie | Maryland | — | — |
| Site 159 | Detroit | Michigan | — | — |
| Site 153 | Minneapolis | Minnesota | — | — |
| Site 145 | Saint Charles | Missouri | — | — |
| Site 130 | St Louis | Missouri | — | — |
| Site 141 | St Louis | Missouri | — | — |
| Site 142 | Clementon | New Jersey | — | — |
| Site 180 | Kenilworth | New Jersey | — | — |
| Site 129 | Albuquerque | New Mexico | — | — |
| Site 131 | Brooklyn | New York | — | — |
| Site 181 | Cedarhurst | New York | — | — |
| Site 169 | Jamaica | New York | — | — |
| Site 195 | New York | New York | — | — |
| Site 147 | Staten Island | New York | — | — |
| Site 127 | Chagrin Falls | Ohio | — | — |
| Site 176 | Cincinnati | Ohio | — | — |
| Site 191 | Oklahoma City | Oklahoma | — | — |
| Site 146 | Philadelphia | Pennsylvania | — | — |
| Site 179 | Philadelphia | Pennsylvania | — | — |
| Site 196 | Sioux Falls | South Dakota | — | — |
| Site 134 | Memphis | Tennessee | — | — |
| Site 170 | Memphis | Tennessee | — | — |
| Site 177 | Austin | Texas | — | — |
| Site 185 | Conroe | Texas | — | — |
| Site 126 | Houston | Texas | — | — |
| Site 151 | San Antonio | Texas | — | — |
| Site 138 | Richmond | Virginia | — | — |
| Site 198 | Spokane | Washington | — | — |
| Site 165 | Huntington | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00347425, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2008 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00347425 live on ClinicalTrials.gov.